Website
News25/Ratings12
News · 26 weeks34-67%
2025-10-262026-04-19
Mix2090d
- Insider11(55%)
- SEC Filings6(30%)
- Other2(10%)
- Earnings1(5%)
Latest news
25 items- SECSEC Form DEFA14A filed by Viridian Therapeutics Inc.DEFA14A - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECSEC Form DEF 14A filed by Viridian Therapeutics Inc.DEF 14A - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECViridian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- PRViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 - - Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24 - - Elegrobart was generally well tolerated in both dose groups with low rates of hearing impairment - - REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for topline readout in Q2 2026; BLA submission anticipated in Q1 2027 - - Viridian ended Q4 2025 with $875 million in cash; the company anticipates exist
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Viridian Therapeutics Inc.SCHEDULE 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
- INSIDERAmendment: Chief Financial Officer Harmon Seth covered exercise/tax liability with 2,031 shares, decreasing direct ownership by 21% to 7,850 units (SEC Form 4)4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERAmendment: Chief Operating Officer Beetham Thomas W. covered exercise/tax liability with 3,048 shares, decreasing direct ownership by 19% to 13,361 units (SEC Form 4)4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERAmendment: Chief Legal Officer Tousignant Jennifer covered exercise/tax liability with 1,675 shares, decreasing direct ownership by 32% to 3,494 units (SEC Form 4)4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERAmendment: President and CEO Mahoney Stephen F. covered exercise/tax liability with 7,408 shares, decreasing direct ownership by 18% to 33,349 units (SEC Form 4)4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERChief Legal Officer Tousignant Jennifer converted options into 5,169 shares and covered exercise/tax liability with 1,724 shares (SEC Form 4)4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERChief Financial Officer Harmon Seth covered exercise/tax liability with 2,091 shares and converted options into 6,267 shares, increasing direct ownership by 116% to 7,790 units (SEC Form 4)4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Financial Officer Harmon Seth4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Legal Officer Tousignant Jennifer4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERChief Operating Officer Beetham Thomas W. converted options into 9,409 shares and covered exercise/tax liability with 3,138 shares, increasing direct ownership by 90% to 13,271 units (SEC Form 4)4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERPresident and CEO Mahoney Stephen F. converted options into 18,357 shares and covered exercise/tax liability with 7,627 shares, increasing direct ownership by 48% to 33,130 units (SEC Form 4)4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Tripuraneni Radhika4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- SECSEC Form S-8 filed by Viridian Therapeutics Inc.S-8 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECSEC Form 10-K filed by Viridian Therapeutics Inc.10-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECViridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- PRViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results- PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch - - Marketing Authorization Application (MAA) for veligrotug for TED submitted to the European Medicines Agency (EMA) in January 2026 - - Phase 3 topline data readout for subcutaneous elegrobart (VRDN‑003) REVEAL‑1 and REVEAL‑2 studies on track for Q1 and Q2 2026 in active and chronic TED, respectively - - Advanced VRDN-008 into phase 1 clinical trial in healthy volunteers; data on track for 2H 2026 - - Strong balance sheet with cash, cash equivalents, and short-term investments of $875 million as of December 31, 2025 -
- PRViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 16,650 shares of the company's common stock to one new employee (the "Inducement Grants") on January 2, 2026 (the "Grant Date"). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the "Plan") but remain subject to the terms and conditions of s
- PRViridian Therapeutics Prepares for Transformational 2026- Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track - - Topline phase 3 results for subcutaneous elegrobart (VRDN-003) on track for Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 for active and chronic TED, respectively - - IND submitted for half-life extended FcRn-inhibitor, VRDN-008; healthy volunteer (HV) data expected in 2H 2026 - - Unveiling new program targeting thyroid-stimulating hormone receptor (TSHR); IND expected Q4 2026 - - Cash position of approximately $888 million as of October 31, 2025 - - Company expects its current business plans to be funded through profita
- INSIDERChief Legal Officer Tousignant Jennifer sold $70,796 worth of shares (2,272 units at $31.16), closing all direct ownership in the company (SEC Form 4)4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- PRViridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease- PDUFA target action date of June 30, 2026 - - Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in the safety or effectiveness of treating a serious condition - - Veligrotug now has both Priority Review and Breakthrough Therapy Designations, each following requests which included data on veligrotug's (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, toda
- ANALYSTWedbush reiterated coverage on Viridian Therapeutics with a new price targetWedbush reiterated coverage of Viridian Therapeutics with a rating of Outperform and set a new price target of $47.00 from $42.00 previously